Lunai Bioworks: Wittekind reports 4.5% stake

The reported share counts reflect Lunai Bioworks' 1-for-8 reverse stock split on May 19, 2026.

Rhea-AI Filing Summary

Lunai Bioworks Inc. reporting person William Anderson Wittekind reports beneficial ownership of 226,665 common shares, equal to 4.5% of the 5,034,452 shares outstanding as of October 13, 2026. The amendment states that he no longer owns more than 5% of the class.

His sole voting and dispositive power covers 70,083 shares, while shared voting and dispositive power covers 156,582 shares. The sole-power amount includes shares owned directly, through Weird Science LLC, and through four trusts for which Wittekind is sole trustee. Shared-power holdings include shares held jointly and shares over which he has voting and dispositive authority through a power of attorney.

Filing Explained

The amendment adds that 155,481 shares reported under Wittekind’s shared voting and dispositive power are owned by his spouse and subject to a federal court writ of attachment, ordered October 27, 2023, to secure plaintiffs’ claim.

Key Figures

Beneficially owned: 226,665 shares Ownership of class: 4.5% Shares outstanding: 5,034,452 shares +2 more

5 metrics

Beneficially owned 226,665 shares Aggregate beneficial ownership

Ownership of class 4.5% Based on shares outstanding as of October 13, 2026

Shares outstanding 5,034,452 shares As of October 13, 2026

Sole voting and dispositive power 70,083 shares Reported by William Anderson Wittekind

Shared voting and dispositive power 156,582 shares Reported by William Anderson Wittekind

Key Terms

beneficially owned, sole voting power, grantor retained annuity trust, power of attorney

4 terms

beneficially owned regulatory

"aggregate amount beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power regulatory

"Wittekind has sole voting power and sole dispositive power"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

grantor retained annuity trust regulatory

"a grantor retained annuity trust of which Wittekind is the sole trustee"

A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.

power of attorney regulatory

"shares voting and dispositive power through a power of attorney"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LNAI shares does William Anderson Wittekind report as beneficially owned?

William Anderson Wittekind reports beneficial ownership of 226,665 LNAI common shares, equal to 4.5% of the 5,034,452 shares outstanding as of October 13, 2026. He reports that he no longer owns more than 5% of the class.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/15/2026 - 09:13 PM EDT Accepted by SEC EDGAR 10/15/2026 - 09:13 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 25)

Lunai Bioworks Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

29350E203

(CUSIP Number)

William Anderson Wittekind
8581 Santa Monica Blvd., #317
West Hollywood, CA, 90069
(424) 235-1810

Patrick T. McCloskey
McCloskey Law PLLC, 260 Madison Avenue, 15th Floor
New York, NY, 10016
646.970.0611

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

10/13/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 29350E203

1

Name of reporting person

William Anderson Wittekind

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 70,083.00
8	Shared Voting Power 156,582.00
9	Sole Dispositive Power 70,083.00
10	Shared Dispositive Power 156,582.00

11

Aggregate amount beneficially owned by each reporting person

226,665.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.5 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

(1) The number of shares disclosed in Rows 7 and 9 consist of (i) 40,822 shares owned by William Anderson Wittekind ("Wittekind"); (ii) 10,504 shares owned by Weird Science LLC ("Weird Science"); (iii) 63,393 shares owned by the William Anderson Wittekind 2020 Annuity Trust, a grantor retained annuity trust of which Wittekind is the sole trustee (the "Wittekind 2020 Annuity Trust"); (iv) 5,632 shares owned by the Dybul 2020 Angel Annuity Trust, a grantor retained trust of which Wittekind is the sole trustee (the "Dybul 2020 Annuity Trust"); (v) 625 shares owned by the Ty Mabry 2021 Annuity Trust, a grantor retained annuity trust of which Wittekind is sole trustee (the "Mabry 2021 Annuity Trust"); and (vi) 4,576 shares owned by the William Anderson Wittekind 2021 Annuity Trust, a grantor retained annuity trust of which Wittekind is the sole trustee (the "Wittekind 2021 Annuity Trust" and, together with the Wittekind 2020 Annuity Trust, the Dybul 2020 Annuity Trust and the Mabry 2021 Annuity Trust, the "Trusts"). In his capacity as the sole manager of Weird Science, Wittekind has sole voting and sole dispositive power over the shares owned by Weird Science. In his capacity as the sole trustee of the Trusts, Wittekind has sole voting power and sole dispositive power over the shares owned by the Trusts. (2) The number of shares disclosed in Rows 8 and 12 consists of (i) 1,102 shares owned by Wittekind and Serhat Gumrukcu, Wittekind's spouse ("Gumrukcu"), as joint tenants with a right of survivorship ("JTWROS") and (ii) 155,481 shares owned by Gumrukcu, of which Wittekind shares voting and dispositive power through a power of attorney dated June 24, 2022. Pursuant to an order of the United States District Court for the District of Vermont dated October 27, 2023, the shares owned by Gumrukcu are subject to a writ of attachment to secure the plaintiffs' claim in The Estate of Gregory Davis et al. v. Serhat Daniel Gumrukcu (Civil Case No. 5:22-cv-123). (3) The share numbers reflect a 1-for-8 reverse stock split that occurred on May 19, 2026. The percentage ownership disclosed in Row 13 is based upon 5,034,452 shares outstanding as of October 13, 2026, as disclosed in the Issuer's Form 10-K filed with the Commission on October 13, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001 per share
(b)	Name of Issuer: Lunai Bioworks Inc.
(c)	Address of Issuer's Principal Executive Offices: 2080 Century Park East, Suite 906, Los Angeles, CALIFORNIA , 90067.
Item 1 Comment: This Amendment No. 25 amends the Schedule 13D filed by Weird Science LLC, a California limited liability company ("Weird Science") and William Anderson Wittekind, a member and manager of Weird Science ("Wittekind") with respect to the shares of common stock, par value $0.0001 per share ("Common Stock") of Lunai Bioworks Inc. (the "Issuer") received by Weird Science pursuant to that certain Agreement and Plan of Merger dated January 12, 2018 (the "Merger Agreement") by and among the Issuer (then known as DanDrit BioTech USA, Inc.), DanDrit Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Issuer ("Merger Sub"), Renovaro Biopharma, Inc., a Delaware corporation then known as Enochian Biopharma Inc. ("Target"), and Weird Science, in its capacity as the majority stockholder of the Target, as amended by Amendment Nos. 1 through 24 thereto. Wittekind is the sole reporting person under this Amendment No. 25 to Schedule 13D (the "Reporting Person"). Capitalized terms used but not defined in this Amendment No. 25 have the meanings given to such terms in the initial Schedule 13D, as amended by Amendment Nos. 1 through 24 thereto. On October 13, 2026 the Issuer filed a Form 10-K reporting that there were 5,034,452 shares of Common Stock issued and outstanding as of October 13, 2026. This Amendment No. 25 is being filed to report the change in the Reporting Person's beneficial ownership to 4.5%.
Item 5.	Interest in Securities of the Issuer
(a)	The information in Items 7-11 and Item 13 of the Cover Page of this Amendment No. 25, including the accompany notes, is hereby incorporated by reference into this Item 5(a).
(b)	The information in Items 7-11 and Item 13 of the Cover Page of this Amendment No. 25, including the accompany notes, is hereby incorporated by reference into this Item 5(b).
(c)	Not Applicable
(d)	Not applicable
(e)	Based on the number of shares of Common Stock disclosed as outstanding in the Issuer's Form 10-K filed on October 13, 2026, the Reporting Person no longer owns more than 5% of the Issuer's Common Stock.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Not Applicable.
Item 7.	Material to be Filed as Exhibits.
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

William Anderson Wittekind

Signature:	/s/ William Anderson Wittekind
Name/Title:	William Anderson Wittekind
Date:	10/15/2026